Lexington backs Rosetta’s direct pharma deal
The life sciences-focused direct secondaries firm has purchased 20 assets thought to be worth $5-10m each with the backing of Lexington Partners.
24 March 2014•1 min read
The life sciences-focused direct secondaries firm has purchased 20 assets thought to be worth $5-10m each with the backing of Lexington Partners.
